Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell
about
Virulence factors of medically important fungiAdaptive immunity to fungiMonoclonal antibodies against peptidorhamnomannans of Scedosporium apiospermum enhance the pathogenicity of the fungusA role for LHC1 in higher order structure and complement binding of the Cryptococcus neoformans capsuleCryptococcal interactions with the host immune system.Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cationsAntibody binding to Cryptococcus neoformans impairs budding by altering capsular mechanical properties.Combinatorial library cloning of human antibodies to Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23FProtection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherenceProtective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsuleAntibodies to the desmoglein 1 precursor proprotein but not to the mature cell surface protein cloned from individuals without pemphigus.Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsuleBivalency is required for anticapsular monoclonal antibodies to optimally suppress activation of the alternative complement pathway by the Cryptococcus neoformans capsule.Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism.A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection.Antibody-mediated protection against Cryptococcus neoformans pulmonary infection is dependent on B cellsThe different binding patterns of two immunoglobulin M monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlate with serotype classification and differences in functional assays.Variants of a Cryptococcus neoformans strain elicit different inflammatory responses in mice.In vitro and in vivo stability of a Cryptococcus neoformans [corrected] glucuronoxylomannan epitope that elicits protective antibodies.Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune miceThe capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibodyAntibody interactions with the capsule of Cryptococcus neoformansBoth Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans.Monoclonal immunoglobulin G1 directed against Aspergillus fumigatus cell wall glycoprotein protects against experimental murine aspergillosisThe common Cryptococcus neoformans glucuronoxylomannan M2 motif elicits non-protective antibodies.Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificityAntibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigenAntifungal agents: chemotherapeutic targets and immunologic strategies.Fungal vaccines and immunotherapeutics.Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis.Hybridoma passage in vitro may result in reduced ability of antimannan antibody to protect against disseminated candidiasisAntibodies produced in response to Cryptococcus neoformans pulmonary infection in mice have characteristics of nonprotective antibodiesA Paracoccidioides brasiliensis glycan shares serologic and functional properties with cryptococcal glucuronoxylomannan.Antibody action after phagocytosis promotes Cryptococcus neoformans and Cryptococcus gattii macrophage exocytosis with biofilm-like microcolony formation.Antibody-mediated immunity against intracellular pathogens: two-dimensional thinking comes full circle.Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.Antibody immunity and invasive fungal infectionsPeroxynitrite contributes to the candidacidal activity of nitric oxide-producing macrophages.
P2860
Q24683790-13E4971B-A846-4379-ACF1-D7CFEA014215Q27025806-F4577863-A5E5-4EAB-B926-61B0A9BE0769Q27306696-D80F631F-592A-477B-86C2-8B4A9A4755A3Q28538344-D23E84A1-D759-48A3-A58E-42D95E3BD857Q30387948-B0C4463A-CE53-41BA-ADAF-6E72C6D937FAQ30479935-6460466B-F8DE-4396-9794-276651473C94Q30530667-3FB8C221-EE3A-440F-83A5-F6DA8ADDC429Q30658618-8CF3CD42-6CEF-4D0D-B9E3-06EB5ECF1FE7Q30862390-B9E764DF-2117-48BC-892E-339E70F474AEQ33261310-EEB1EBBC-BFF9-4A27-AB89-8882A77E88A2Q33386722-E3A8B69A-B9E1-4D7C-BB16-FE51AA0C205EQ33693515-0651BC99-E1F8-440E-970D-65C724D84C89Q33752366-178E0295-7217-4CFF-9342-AEBF8C9794C3Q33752377-A61E29CD-1820-43B0-BE20-B43B6163CD68Q33755308-E1CF83CF-AEA4-4C3F-8D82-6FA9BB3B4143Q33768705-454594EC-E96C-4DF1-8724-96B3AB796C49Q33793546-678E396B-FAED-433F-AFB0-CCAC0AAA130CQ33991158-6A49757E-0D2F-49C2-9D79-17164F3327E2Q33997697-6F6723A6-CADA-4783-B38E-3E1133633F1BQ34001243-24F6E513-A633-4D10-860A-3B235FC45D57Q34001701-E765DAA0-EB2E-4838-9AE6-65982771AFAAQ34001769-D29E6F5B-DCD3-40CF-A661-23103E01B898Q34004832-AE9F863C-E8E0-4463-8AB5-59058540C67BQ34009446-75C376A6-B22E-4AEB-8FF2-5A5A5658A2EAQ34045440-2F91E811-7AB7-4930-A258-261FFFAEADC3Q34099803-93B00A09-E05A-4FC2-BC4C-D16EB69333CAQ34123230-6E5E24F3-EF97-4376-82B8-923A967B8514Q34146715-7E53C942-82D5-4B35-A0DE-7D2727B91D1FQ34400044-FB8CD69C-6035-489D-899F-51FC68222AF3Q34400249-FED38F00-0178-4AAB-BC86-4F2870EC91E2Q34594241-355988F8-2A6F-434A-93EE-152C2AE4420EQ34721320-D9E0A47D-A31D-4FF5-A570-AE1C9159624EQ34757345-997DEE94-F396-4FF7-ABF1-FDC030B27BB5Q34907746-C52393CB-035E-4DA7-9994-24521B465ED8Q34961134-7A4BF704-A158-43E6-813B-2695F59AC98EQ35182322-FDEA9BA0-52CA-4BFC-B8B2-7A92F2DF65D3Q35428887-FA1AEF16-A283-4260-92C6-DCC246A5F3B5Q35434901-1E3C43A9-6BF5-477E-9C87-50DE769F1C66Q35447692-48B52AAA-29AB-49E0-9379-6658F3276FFAQ35511088-088D881A-8E5A-4B45-8DAA-6485F20166FB
P2860
Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Protective and nonprotective m ...... ns originating from one B cell
@ast
Protective and nonprotective m ...... ns originating from one B cell
@en
type
label
Protective and nonprotective m ...... ns originating from one B cell
@ast
Protective and nonprotective m ...... ns originating from one B cell
@en
prefLabel
Protective and nonprotective m ...... ns originating from one B cell
@ast
Protective and nonprotective m ...... ns originating from one B cell
@en
P2093
P2860
P356
P1476
Protective and nonprotective m ...... ns originating from one B cell
@en
P2093
Casadevall A
Mukherjee J
Nussbaum G
Scharff MD
P2860
P304
P356
10.1084/JEM.181.1.405
P407
P577
1995-01-01T00:00:00Z